MARKET

IDXG

IDXG

Interpace Biosciences Inc
OTCID
4.500
-0.100
-2.17%
Closed 14:36 11/20 EST
OPEN
4.600
PREV CLOSE
4.600
HIGH
4.600
LOW
4.440
VOLUME
2.80K
TURNOVER
12.62K
52 WEEK HIGH
12.00
52 WEEK LOW
3.850
MARKET CAP
24.93M
P/E (TTM)
1.020
1D
5D
1M
3M
1Y
5Y
1D
*Interpace Biosciences Withdraws Securities Offering Due to Current Market Conditions
Dow Jones · 3d ago
Interpace Biosciences Q3 Revenue Rises 18%; Advances Pancreatic Cancer Program
NASDAQ · 4d ago
Interpace Biosciences GAAP EPS of -$0.26, revenue of $10.4M
Seeking Alpha · 5d ago
Weekly Report: what happened at IDXG last week (1109-1113)?
Weekly Report · 5d ago
Weekly Report: what happened at IDXG last week (1102-1106)?
Weekly Report · 11/09 10:03
Weekly Report: what happened at IDXG last week (1026-1030)?
Weekly Report · 11/02 10:03
Weekly Report: what happened at IDXG last week (1019-1023)?
Weekly Report · 10/26 10:03
Weekly Report: what happened at IDXG last week (1012-1016)?
Weekly Report · 10/19 10:03
More
About IDXG
Interpace Biosciences, Inc. provides esoteric molecular diagnostic testing and pathology services to aid physicians in the evaluation of cancer risk. The Company’s clinical services business commercializes clinically useful molecular diagnostic tests and molecular pathology services. The Company develops and commercializes genomic tests and related first-line assays that can personalize medicine to help improve patient diagnosis and management. It has five commercialized molecular diagnostic tests: PancraGEN, PanDNA, ThyGeNEXT, ThyraMIR v2, and RespriDX. PancraGEN is a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians’ better risk-stratify pancreaticobiliary cancers using the Company’s proprietary PathFinderTG platform. PanDNA is an alternate reporting option of the PathFinderTG platform, which provides physicians the molecular only information. ThyGeNEXT is an oncogenic mutation panel that helps rule-in and rule-out malignancy in thyroid nodules.

Webull offers Interpace Biosciences Inc stock information, including OTCID: IDXG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDXG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IDXG stock methods without spending real money on the virtual paper trading platform.